C12N 2740/15042
Virus or viral particle as vehicle
Official title: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N2740/15042 (Virus or viral particle as vehicle) appears on 26 US grants and 64 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 64
- Assignees
- 51
- Inventors
- 141
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 1 | 4 |
| 2016 | 0 | 2 |
| 2017 | 1 | 2 |
| 2018 | 2 | 2 |
| 2019 | 0 | 3 |
| 2020 | 1 | 7 |
| 2021 | 5 | 5 |
| 2022 | 1 | 17 |
| 2023 | 4 | 2 |
| 2024 | 3 | 12 |
| 2025 | 5 | 4 |
| 2026 | 3 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene22 Sep 2026US 12,742,179 B2National Jewish Health
- Method for transduction of t cells in the presence of malignant cells4 Aug 2026US 12,698,315 B2Miltenyi Biotec GmbH
- P21 expressing monocytes for cancer cell therapy6 Jan 2026US 12,514,902 B2Institut Gustave Roussy
- Chimeric antigen receptor targeting CLL1 and use thereof30 Dec 2025US 12,508,312 B2Guangzhou Bio-Gene Technology Co., Ltd
- SIRPα-silenced natural killer (NK) cells19 Aug 2025US 12,391,923 B2The Regents of the University of California
- Engineered enveloped vectors and methods of use thereof21 May 2026US 2026/0139247 A1GigaMune, Inc.
- P21 Expressing Monocytes for Cancer Cell Therapy5 Mar 2026US 2026/0061029 A1Institut Gustave Roussy
- Sirpalpha-silenced natural killer (nk) cells5 Mar 2026US 2026/0062675 A1The Regents of the University of California
- Transient expression system for rna, for vaccination12 Feb 2026US 2026/0041746 A1Geg Tech
- Modified rhabdovirus glycoproteins and uses thereof6 Nov 2025US 2025/0339384 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Pseudotyped lentiviral vectors4US 10,072,273 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) · 2018
- Methods and composition for gene delivery using an engineered viral particle4US 11,191,784 B2The Trustees of the University of Pennsylvania · 2021
- Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene3US 11,932,867 B2National Jewish Health · 2024
- WNT7A compositions and method of using the same2US 9,732,130 B2Ottawa Hospital Research Institute · 2017
- Method for modifying human cell lines to produce factor VII1US 10,590,405 B2FundaçãO Hemocentro De RibeirãO Preto—Fundherp · 2020